Sign In
Upcoming Event
Free Newsletter
Emergent BioSolutions can pursue chikungunya vaccine in Europe
Emergent BioSolutions can pursue chikungunya vaccine in Europe
Listen to this article
Emergent BioSolutions Inc., a Gaithersburg life sciences firm that makes products to address public health threats, has an agreement with the European Medicines Agency to pursue its proposed development plan for a vaccine candidate.
The company received approval for its plan to develop a vaccine candidate for chikungunya virus, which people can get from infected mosquitoes. Emergent has proposed using serum neutralizing antibodies, which defend cells from infection, to predict the clinical benefit of the vaccine candidate.
The vaccine candidate is now being researched in roughly 430 healthy adults at three sites in America. It is licensed from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. It received fast track designation from the U.S. Food and Drug Administration in May 2018.
